Intellia Therapeutics, Inc. Announces Key Amendments to Corporate By-laws

Comprehensive Update Filed with SEC: Potential Impact for Shareholders

Intellia Therapeutics, Inc. (NASDAQ: NTLA) has filed a Form 8-K with the Securities and Exchange Commission, reporting significant amendments to its corporate by-laws. The changes, adopted by the Board of Directors on April 7, 2026, are encapsulated in the Fourth Amended and Restated By-laws, which now govern shareholder meetings, director nominations, and business proposals. These updates are effective as of the filing date and could have important implications for shareholders and the governance of the company.

Key Points from the SEC Filing

• Amendments to By-laws: The Board, following recommendations from the nominating and corporate governance committee, approved substantial updates to the company’s Third Amended and Restated By-laws, resulting in the Fourth Amended and Restated By-laws.
• Enhanced Shareholder Proposal and Nomination Procedures: The new by-laws clarify and tighten requirements for shareholders who wish to nominate directors or propose business for the annual meeting. Shareholders must follow detailed notice timelines and provide extensive information about nominees, business proposals, and their own holdings and affiliations.
• Proxy and Solicitation Representations: Shareholders making nominations or proposals must disclose whether they intend to deliver a proxy statement and form of proxy to other shareholders, indicating the level of support expected for their nominees or proposals. This “Solicitation Statement” is a new requirement.
• Deficiency Notification and Cure Period: The by-laws introduce a mechanism for the company to notify shareholders of deficiencies in their nomination or proposal notices. Shareholders will have a specified period to cure such deficiencies, failing which their proposals may be excluded.
• Compliance with Federal Securities Laws: Shareholders must comply with all applicable rules under the Exchange Act, including Rule 14a-8 and Rule 14a-19, in addition to the by-law requirements. Failure to comply will result in proposals or nominations being disregarded.
• Limits on Director Nominations: Shareholders can nominate only as many candidates as there are directorships up for election at the annual meeting. Substitute nominees are allowed only if timely notice is provided with all required information.
• Meeting Procedures and Adjournments: The Board retains broad authority to postpone, reschedule, or cancel shareholder meetings, and no new notice period will be triggered by such changes.
• Electronic Notices and Waivers: The by-laws facilitate modern communication by allowing notices and waivers to be delivered electronically, streamlining shareholder interactions.
• Copy of Amended By-laws: The full text of the Fourth Amended and Restated By-laws is provided as Exhibit 3.1 to the 8-K filing.

Potentially Price-Sensitive and Shareholder-Relevant Changes

• Governance and Shareholder Rights: The comprehensive overhaul of procedures for director nominations and business proposals may alter the dynamics of shareholder activism and influence at Intellia. It could affect the ease with which shareholders can effect changes or challenge the Board, potentially impacting future proxy contests or activist campaigns.
• Transparency and Accountability: The new requirements for detailed disclosures and updates are likely to increase transparency, but may also raise the bar for shareholder participation in governance matters.
• Board Authority and Flexibility: The explicit authority of the Board to postpone, reschedule, or cancel meetings without triggering new notice periods consolidates Board control over the timing and conduct of shareholder meetings.
• Impact on Shareholder Engagement: These changes could affect the value perception among current and prospective shareholders, especially those interested in active engagement or governance reforms.
• Legal and Regulatory Compliance: The by-law amendments reinforce compliance with federal securities laws, reducing risk of procedural errors that could invalidate shareholder actions or expose the company to legal challenges.

Additional Details

• Intellia Common Stock: The company’s common stock (par value \$0.0001 per share) continues to trade under the symbol “NTLA” on the Nasdaq Global Market.
• Emerging Growth Company Status: Intellia has indicated it is no longer an emerging growth company under SEC definitions, suggesting a maturation in its lifecycle and regulatory profile.
• Corporate Address: The principal executive office remains at 40 Erie Street, Suite 130, Cambridge, MA 02139.
• Signatory: The filing was signed by John M. Leonard, Chief Executive Officer and President.

Exhibits

• Exhibit 3.1: Fourth Amended and Restated By-laws of Intellia Therapeutics, Inc., dated April 7, 2026.
• Exhibit 104: Cover Page Interactive Data File (embedded within the Inline XBRL document).

Conclusion

The amendments to Intellia Therapeutics’ by-laws represent a major update to its corporate governance framework. Shareholders should closely review the new requirements for nominations and proposals, as these could affect their ability to influence company direction and participate in annual meetings. The Board’s enhanced authority to manage meetings and its new mechanisms for addressing shareholder notices may also impact future corporate actions and shareholder engagement. Investors should consider the potential implications of these changes for the company’s governance, shareholder value, and risk profile.

Disclaimer: This article is based on information contained in Intellia Therapeutics, Inc.’s SEC Form 8-K filing as of April 2026. It is provided for informational purposes only and does not constitute investment advice or a recommendation to buy or sell any securities. Investors should conduct their own due diligence and consult with professional advisors before making any investment decisions.

View Intellia Therapeutics, Inc. Historical chart here